Evaro, an NHS-licensed healthcare integration company, has closed a $25 million Series A funding round to accelerate the development of its embedded healthcare infrastructure and broaden its clinical reach. The round was led by AlbionVC, with participation from Exceptional Ventures, Simplyhealth Ventures, Cornerstone VC, and BBI. As part of the transaction, Christoph Ruedig, partner at AlbionVC, will join Evaro’s board of directors.
Evaro provides third-party platforms with the ability to embed regulated healthcare services directly into their user experiences. Its infrastructure supports a range of clinical and operational functions, including consultations, remote diagnostics, prescribing, dispensing, and follow-up care. The company works with consumer brands, healthcare providers, and employers looking to deploy healthcare offerings or benefits without building regulated systems from scratch.
The new funding will be used to expand Evaro’s footprint across women’s health, longevity medicine, and men’s health. The company also plans to strengthen its clinical capabilities in diagnostics and aftercare, while further enhancing its API to support more complex integrations and higher service volumes. This strategy reflects growing demand from non-traditional healthcare players seeking compliant ways to offer clinical services within existing digital products.
“We’ve seen embedded finance transform banking, Evaro is now driving the embedded health revolution,” Ruedig said. “Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials. This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS. We are thrilled to back the team as they define this new category.”
Evaro’s existing partners include period-tracking app Clue and sexual wellness retailer Lovehoney, both of which use Evaro’s infrastructure to provide prescription services to their customers. In 2025, Evaro partnered with Clue to enable UK-based users to access NHS-funded contraception through embedded pharmacy services. Through that integration, users complete an online consultation within the Clue app before Evaro clinicians review and approve prescriptions. Eligible users can access up to 40 NHS-funded oral contraception options, with prescriptions fulfilled via Evaro’s platform and delivered next day.
Founded as an infrastructure-first healthcare company, Evaro positions itself as an enabler for brands seeking to enter regulated healthcare markets while maintaining clinical governance. The company previously raised $1.5 million in seed funding in 2024, and the Series A marks its first significant scale-up round as it expands into new clinical practice areas.
Click here for the original news story.